Friday, May 9, 2025 5/9/2025

PSMA-PET to Guide Prostatectomy: Can PSMA-PET Appropriately Modify Surgery, Reduce Nerve Damage and Optimize Quality-of-Life?

Award Number: R01CA258994
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

PSMA-PET to Guide Prostatectomy: Can PSMA-PET Appropriately Modify Surgery, Reduce Nerve Damage and Optimize Quality-of-Life? - Project Summary/Abstract The 68Ga-P16-093 radiopharmaceutical is an investigational agent that targets prostate specific membrane antigen (PSMA), which is highly expressed in most prostate cancers. PSMA-PET has not been validated as a tool for guiding surgical resection of primary prostate cancer. The objective of this Phase II Clinical Trial is to critically test the ability of 68Ga-P16-093 PET to identify extra- prostatic extension of prostate cancer, to guide surgical resection, and to improve the patient’s post-surgical quality-of-life. For prostate cancer patients who require prostatectomy, we hypothesize that PSMA-PET findings will accurately differentiate patients who can safely undergo nerve-sparing and/or muscle-sparing surgery from those in whom more aggressive wide resection is essential for cancer control; thus, optimizing quality-of-life outcomes. Therefore, the project has two complementary yet independent Specific Aims: Aim 1. To measure the accuracy of both 68Ga-P16-093 PET-CT, and conventional standard-of-care mpMRI, for presurgical detection of extra-prostatic extension. Aim 2. To measure treatment modifications, and patient quality-of-life outcomes, that result from 68Ga- P16-093 -PET incorporation into surgical planning. The innovations of this project are the application of this imaging technology in pre-surgical treatment planning for newly diagnosed disease; the definitive assessment of agent performance in a surgical randomized controlled trial; and the detailed assessments of imaging impact on both surgical planning and subsequent patient clinical outcome. As a control group, one-half of the enrolled subjects will receive their standard-of-care prostatectomy with surgical planning supported only by multiparametric MRI and biopsy findings. The other half of the subjects will be randomized to also receive pre-surgical pelvic imaging with 68Ga-P16-093 PET/CT for independent assessment of the location and extent of disease. The radiology MRI and PET readers will be blinded to the findings of the other modality. The surgeon will receive reports on all imaging, but must document a standard-of-care surgical plan before receiving the PET findings. The surgeon will then document whether, and how, the PET information modifies their prior surgical plan. For validation of imaging findings, whole mount pathology will serve as the “gold standard” for characterization of disease. Patient outcome measures, and cancer recurrence, will be tracked for 18-months following surgery. Our preliminary studies indicate 68Ga-P16-093 PET-CT will show higher accuracy than mpMRI for detection of extra-prostatic extension. And, that the PET-directed surgical modifications will frequently result in appropriate preservation of nerves and muscle, thereby improving post-treatment quality-of-life for many patients, while also helping to avoid positive surgical margins.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $542,612 )
2025	2025	TRUSTEES OF INDIANA UNIVERSITY	980 INDIANA AVE RM 2232	INDIANAPOLIS	IN	46202	MARION	USA	Cancer Detection and Diagnosis Research	000	4	3/3/2025	NON-COMPETING CONTINUATION	$542,612
														Subtotal = $542,612

Issue Date FY: 2024 ( Subtotal = $572,758 )
2024	2024	TRUSTEES OF INDIANA UNIVERSITY	980 INDIANA AVE RM 2232	INDIANAPOLIS	IN	46202	MARION	USA	Cancer Detection and Diagnosis Research	000	3	2/16/2024	NON-COMPETING CONTINUATION	$542,612
2024	2024	TRUSTEES OF INDIANA UNIVERSITY	980 INDIANA AVE RM 2232	INDIANAPOLIS	IN	46202	MARION	USA	Cancer Detection and Diagnosis Research	001	3	4/17/2024	NON-COMPETING CONTINUATION	$30,146
														Subtotal = $572,758

Issue Date FY: 2023 ( Subtotal = $595,230 )
2023	2023	TRUSTEES OF INDIANA UNIVERSITY	980 INDIANA AVE RM 2232	INDIANAPOLIS	IN	46202	MARION	USA	Cancer Detection and Diagnosis Research	000	2	2/28/2023	NON-COMPETING CONTINUATION	$595,230
														Subtotal = $595,230

Issue Date FY: 2022 ( Subtotal = $637,698 )
2022	2022	TRUSTEES OF INDIANA UNIVERSITY	980 INDIANA AVE RM 2232	INDIANAPOLIS	IN	46202	MARION	USA	Cancer Detection and Diagnosis Research	000	1	2/25/2022	NEW	$637,698
														Subtotal = $637,698

Grand Total All Awards = $2,348,298

Top

All Categories

About

Search

Reports

Data Submission

Award Information

PSMA-PET to Guide Prostatectomy: Can PSMA-PET Appropriately Modify Surgery, Reduce Nerve Damage and Optimize Quality-of-Life?

Award Number: R01CA258994

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer